MCRB - Seres Therapeutics, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
7.81
-0.25 (-3.10%)
At close: 4:00PM EDT

7.81 0.00 (0.00%)
After hours: 4:25PM EDT

Stock chart is not supported by your current browser
Previous Close8.06
Open8.10
Bid7.73 x 1400
Ask8.50 x 900
Day's Range7.69 - 8.10
52 Week Range6.65 - 17.42
Volume61,517
Avg. Volume135,865
Market Cap318.614M
Beta0.42
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • Thomson Reuters StreetEvents17 days ago

    Edited Transcript of MCRB earnings conference call or presentation 2-Aug-18 12:30pm GMT

    Q2 2018 Seres Therapeutics Inc Earnings Call

  • Seres Therapeutics (MCRB) Reports Q2 Loss, Lags Revenue Estimates
    Zacks18 days ago

    Seres Therapeutics (MCRB) Reports Q2 Loss, Lags Revenue Estimates

    Seres Therapeutics (MCRB) delivered earnings and revenue surprises of 1.45% and -11.56%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?

  • Associated Press18 days ago

    Seres Therapeutics: 2Q Earnings Snapshot

    On a per-share basis, the Cambridge, Massachusetts-based company said it had a loss of 68 cents. The results surpassed Wall Street expectations. The average estimate of four analysts surveyed by Zacks ...

  • 3 Cheapest Stocks With Greatest Potential for Growth
    InvestorPlace3 months ago

    3 Cheapest Stocks With Greatest Potential for Growth

    Often, publicly-traded companies that trade in discount-bin valuations are there for a reason. When it becomes clear that success is no longer probable, astute investors bail, leaving others holding the bag.

  • Thomson Reuters StreetEvents3 months ago

    Edited Transcript of MCRB earnings conference call or presentation 9-May-18 12:30pm GMT

    Q1 2018 Seres Therapeutics Inc Earnings Call

  • Associated Press3 months ago

    Seres Therapeutics: 1Q Earnings Snapshot

    The Cambridge, Massachusetts-based company said it had a loss of 69 cents per share. The results beat Wall Street expectations. The average estimate of three analysts surveyed by Zacks Investment Research ...

  • Thomson Reuters StreetEvents5 months ago

    Edited Transcript of MCRB earnings conference call or presentation 8-Mar-18 1:00pm GMT

    Q4 2017 Seres Therapeutics Inc Earnings Call

  • Capital Cube8 months ago

    ETFs with exposure to Seres Therapeutics, Inc. : December 26, 2017

    Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to Seres Therapeutics, Inc. Here are 5 ETFs with the largest exposure to MCRB-US. Comparing the performance and risk of Seres Therapeutics, Inc. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker ... Read more (Read more...)

  • Seres Therapeutics, Inc. is trading above its 50 day moving average : MCRB-US : December 20, 2017
    Capital Cube8 months ago

    Seres Therapeutics, Inc. is trading above its 50 day moving average : MCRB-US : December 20, 2017

    Categories: ETFs Yahoo FinanceGet full CapitalCube analysis *Disclaimer : This is as of previous day’s closing price. Technical Indicators Below is a quick look at 5 technical indicators for Seres Therapeutics, Inc.. More studies are available on the Technical Chart. Indicator Signal Closing Price above/below 50 Day Moving Average Bullish Closing Price above/below 200 Day Moving Average Bearish ... Read more (Read more...)

  • American City Business Journals9 months ago

    Seres teams up with MD Anderson to explore gut's role in drug response

    Scientists at MD Anderson Cancer Center in Texas recently showed that the makeup of a person’s microbiome — the trillions of bacteria living in the gut — could help determine whether immunotherapy treatments will work or fail. Now researchers there are planning to further test that concept through a partnership with Seres Therapeutics (MCRB), a Cambridge startup developing microbiome drugs, as well as the Parker Institute, a research collaboration formed by tech entrepreneur Sean Parker. Seres, MD Anderson and the Parker Institute announced Tuesday that they will launch a trial in which patients with advanced metastatic melanoma will either receive a fecal transplant, a live biologic provided by Seres, or a placebo.

  • Thomson Reuters StreetEvents9 months ago

    Edited Transcript of MCRB earnings conference call or presentation 8-Nov-17 1:00pm GMT

    Q3 2017 Seres Therapeutics Inc Earnings Call

  • Associated Press9 months ago

    Seres Therapeutics reports 3Q loss

    On a per-share basis, the Cambridge, Massachusetts-based company said it had a loss of 17 cents. The results exceeded Wall Street expectations. The average estimate of seven analysts surveyed by Zacks ...

  • Capital Cube10 months ago

    ETFs with exposure to Seres Therapeutics, Inc. : October 17, 2017

    Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to Seres Therapeutics, Inc. Here are 5 ETFs with the largest exposure to MCRB-US. Comparing the performance and risk of Seres Therapeutics, Inc. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker ... Read more (Read more...)

  • Seres Therapeutics, Inc. breached its 50 day moving average in a Bearish Manner : MCRB-US : October 3, 2017
    Capital Cube11 months ago

    Seres Therapeutics, Inc. breached its 50 day moving average in a Bearish Manner : MCRB-US : October 3, 2017

    Categories: ETFs Yahoo FinanceGet full CapitalCube analysis *Disclaimer : This is as of previous day’s closing price. Technical Indicators Below is a quick look at 5 technical indicators for Seres Therapeutics, Inc.. More studies are available on the Technical Chart. Indicator Signal Closing Price above/below 50 Day Moving Average Bearish Closing Price above/below 200 Day Moving Average Bullish ... Read more (Read more...)

  • How Should You Think About Seres Therapeutics Inc’s (MCRB) Risks?
    Simply Wall St.11 months ago

    How Should You Think About Seres Therapeutics Inc’s (MCRB) Risks?

    For Seres Therapeutics Inc’s (NASDAQ:MCRB) shareholders, and also potential investors in the stock, understanding how the stock’s risk and return characteristics can impact your portfolio is important. MCRB is exposedRead More...

  • Why Seres Therapeutics Inc. Stock Is Tanking Today
    Motley Fool11 months ago

    Why Seres Therapeutics Inc. Stock Is Tanking Today

    Results from a phase 1 study failed to impress investors.

  • Seres Therapeutics, Inc. :MCRB-US: Earnings Analysis: Q2, 2017 By the Numbers : September 20, 2017
    Capital Cube11 months ago

    Seres Therapeutics, Inc. :MCRB-US: Earnings Analysis: Q2, 2017 By the Numbers : September 20, 2017

    Categories: Yahoo FinanceGet free summary analysis Seres Therapeutics, Inc. reports financial results for the quarter ended June 30, 2017. We analyze the earnings along side the following peers of Seres Therapeutics, Inc. – Xencor, Inc., Acceleron Pharma Inc, Bellicum Pharmaceuticals Inc and Intrexon Corporation (XNCR-US, XLRN-US, BLCM-US and XON-US) that have also reported for this period. Highlights ... Read more (Read more...)